<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877214</url>
  </required_header>
  <id_info>
    <org_study_id>NHL 7-2008</org_study_id>
    <nct_id>NCT00877214</nct_id>
  </id_info>
  <brief_title>Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas</brief_title>
  <acronym>MAINTAIN</acronym>
  <official_title>Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jurgen Barth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sponsor GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an extended maintenance therapy with Rituximab&#xD;
      in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has&#xD;
      advantages compared to a shorter or no maintenance therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results from several randomised studies show a clinical benefit of a maintenance therapy with&#xD;
      rituximab in follicular lymphomas. The advantage of a maintenance therapy in other indolent&#xD;
      and mantle cell lymphomas is - due to the lower incidence of these diseases- not well&#xD;
      investigated.&#xD;
&#xD;
      This study tries to determine the significance of an extended maintenance therapy with&#xD;
      rituximab in follicular lymphomas and the significance of a maintenance therapy other&#xD;
      indolent and mantle cell lymphomas compared to observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2009</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years and ongoing</time_frame>
    <description>Time from randomization until progress or death of any course</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate and duration; event free-, progression free-, disease free- and over all survival</measure>
    <time_frame>5 years and ongoing</time_frame>
    <description>Time from randomization until treatment failure due to progression or not achieving any remission; time from achievin CR or PR until progression or relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1272</enrollment>
  <condition>Follicular Lymphomas</condition>
  <condition>Immunocytomas</condition>
  <condition>Marginal Zone Lymphomas</condition>
  <condition>Mantle-Cell Lymphomas</condition>
  <condition>Lymphocytic Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab / Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Mabthera(R)</other_name>
    <other_name>Rituxan(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab / observation</intervention_name>
    <description>Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Mabthera(R)</other_name>
    <other_name>Rituxan(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histological verified CD20-positive B-Cell-Lymphoma of the following&#xD;
             entities:&#xD;
&#xD;
               -  Follicular Lymphoma Grade 1 and 2&#xD;
&#xD;
               -  Lymphoplasmocytic lymphoma / Immunocytoma (Morbus Waldenström) and small cell&#xD;
                  lymphocytic lymphoma (CLL without leukemic hemogram)&#xD;
&#xD;
               -  Marginal zone lymphoma, nodal and extra nodal&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
          -  No prior therapy with cytotoxics, interferon or monoclonal antibodies&#xD;
&#xD;
          -  Need for therapy, except mantle cell lymphomas&#xD;
&#xD;
          -  Stadium III or IV or Stadium with II bulky disease (&gt; 7 cm diameter, or 3 lesions &gt; 5&#xD;
             cm)&#xD;
&#xD;
          -  General condition WHO 0-2&#xD;
&#xD;
          -  Age min. 18 years, max. 80 years&#xD;
&#xD;
          -  Negative pregnancy test, contraceptives mandatory for women of child-bearing age&#xD;
&#xD;
          -  Actual histology, not older than 6 months required&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not meeting the inclusion criteria above&#xD;
&#xD;
          -  Possibility of a primary radiation therapy with curative intention&#xD;
&#xD;
          -  Pretreatment, except a single, localized radiation therapy (radiation field not larger&#xD;
             than 2 adjacent lymph node regions)&#xD;
&#xD;
          -  Co-morbidities, excluding a therapy according to the protocol:&#xD;
&#xD;
               -  severe, medicinal not adjustable hypertension&#xD;
&#xD;
               -  severe limited capacity of the heart (NYHA III or IV), the lung (WHO-Grade III or&#xD;
                  IV), the liver and kidneys (creatinin &gt; 2 mg/dl, GOT and GPT or bilirubin 3 x&#xD;
                  ULN), except if caused by lymphoma&#xD;
&#xD;
               -  severe, medicinal not adjustable diabetes mellitus&#xD;
&#xD;
               -  active autoimmune disease&#xD;
&#xD;
               -  active infection, requiring antibiotic therapy&#xD;
&#xD;
          -  Patients with proven HIV-infection&#xD;
&#xD;
          -  Active replicating hepatitis-Infection&#xD;
&#xD;
          -  Severe psychiatric diseases&#xD;
&#xD;
          -  Lacking or anticipated non-compliance&#xD;
&#xD;
          -  Known hypersensitivity against the active components or additives or mouse- proteins&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Patients with a secondary malignancy or malignant disease in his history if, curative&#xD;
             surgery can not be doubtless assured .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Rummel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Giessen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>StiL Head Office; Justus-Liebig-University</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stil-info.de</url>
    <description>Homepage of the Study group of indolent lymphomas (StiL)</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Jurgen Barth</investigator_full_name>
    <investigator_title>Professor Mathias Rummel</investigator_title>
  </responsible_party>
  <keyword>Bendamustine</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Significance of maintenance therapy</keyword>
  <keyword>Efficacy and safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

